You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Moodys
Mallinckrodt
Colorcon
McKesson

Last Updated: March 8, 2021

DrugPatentWatch Database Preview

NATPARA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for NATPARA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Entera Bio Ltd.Phase 2
ShirePhase 1
University of BergenPhase 0

See all NATPARA clinical trials

Recent Litigation for NATPARA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Ravgen, Inc. v. Progenity, Inc.2020-12-20
Juul Labs Inc v. EZfumes2020-07-10
Genentech, Inc. v. Samsung Bioepis Co. Ltd.2020-06-28

See all NATPARA litigation

PTAB Litigation
PetitionerDate
2018-07-13
2017-07-28
Pfizer, Inc.2017-05-19

See all NATPARA litigation

Pharmacology for NATPARA
Ingredient-typeParathyroid Hormone

Company Disclosures: US Patents for NATPARA

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial Allelix BioPharmaceuticals Inc. (Ontario, CA) 2039-03-29 RX Orphan company
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial Allelix BioPharmaceuticals Inc. (Ontario, CA) 2039-03-29 RX Orphan company
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial Allelix BioPharmaceuticals Inc. (Ontario, CA) 2039-03-29 RX Orphan company
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Start Trial Allelix BioPharmaceuticals Inc. (Ontario, CA) 2039-03-29 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for NATPARA

These patents were identified by searching patent claims

Supplementary Protection Certificates for NATPARA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
CA 2005 00027 Denmark   Start Trial PRODUCT NAME: CINACALCET ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER HYDROCHLORIDET
C00911342/01 Switzerland   Start Trial PRODUCT NAME: DENOSUMABUM; REGISTRATION NO/DATE: SWISSMEDIC 60210 03.08.2010
91759 Luxembourg   Start Trial 91759, EXPIRES: 20230415
C300741 Netherlands   Start Trial PRODUCT NAME: CICLOSPORINE (EYE DROP; REGISTRATION NO/DATE: EU/1/15/990 20150319
1090038-9.L Sweden   Start Trial PRODUCT NAME: DENOSUMAB; REG. NO/DATE: EU/1/10/618/001 20100526
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Express Scripts
McKinsey
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.